Flash labelling of S‐phase cells in short‐term organ culture of normal and pathological human endometrium using bromodeoxyuridine and tritiated thymidine

Thornton, Jim; Wells, Michael; Hume, W.J.

doi:10.1002/path.1711540407

Cited by 40 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BrdU labeling is comparable to [ 3 H]thymidine for analysis of LI, and use of this nonradioactive thymidine analogue has made it possible to study LI in vivo in large mammals, including primates [6,11,31,32]. The effect of estrogen on endometrial LI was readily apparent.…”

Section: Discussionmentioning

confidence: 97%

Effects of Ovarian Steroids on Uterine Growth, Morphology, and Cell Proliferation in Ovariectomized, Steroid-Treated Ewes1

Johnson

Redmer

Reynolds

1997

Biology of Reproduction

View full text Add to dashboard Cite

Uterine growth, morphology, and endometrial cell proliferation were evaluated in intact estrous (EST; Day 0 of the estrous cycle) or luteal (LUT; Day 10 of the estrous cycle) ewes or in ovariectomized ewes receiving no hormone (OVX); estradiol-17beta (OVX+E); progesterone for 8 (OVX+P8), 30 (OVX+P30), or 60 (OVX+P60) days; estradiol followed by progesterone (OVX+E+P); or progesterone followed by estradiol (OVX +P+E). Uterine weights were greater for EST than for LUT ewes, were reduced 2- to 4-fold in OVX ewes, and were increased in estradiol-treated (OVX+E, OVX+E+P, and OVX+P+E) ewes. The effects of estradiol treatment on uterine growth in OVX ewes were primarily on cellular hypertrophy rather than hyperplasia. Endometrial labeling index (LI) was greater for EST than for LUT ewes and was low in OVX ewes. Compared with OVX ewes, OVX+E and OVX+P+E ewes had increased LI for all endometrial tissues, whereas OVX+P8 and OVX+E+P ewes had increased LI only for luminal epithelium. These data will help us determine the mechanisms by which ovarian steroids regulate uterine growth in ewes.

show abstract

Section: Discussionmentioning

confidence: 97%

Effects of Ovarian Steroids on Uterine Growth, Morphology, and Cell Proliferation in Ovariectomized, Steroid-Treated Ewes1

Johnson

Redmer

Reynolds

1997

Biology of Reproduction

View full text Add to dashboard Cite

show abstract

“…This immunohistochemical method allows measurement of the SPF without the need for autoradiography or radioisotopes and has been shown to give similar results to 3 HTdR labelling [17]. Further work by Meyer and colleagues found BrdU labelling of breast cancer specimens to correlate with S-phase measured by 3 HTdR [18] and flow cytometry [14].…”

Section: S-phasementioning

confidence: 99%

Measuring proliferation in breast cancer: practicalities and applications

2006

View full text Add to dashboard Cite

Various methods are available for the measurement of proliferation rates in tumours, including mitotic counts, estimation of the fraction of cells in S-phase of the cell cycle and immunohistochemistry of proliferation-associated antigens. The evidence, advantages and disadvantages for each of these methods along with other novel approaches is reviewed in relation to breast cancer. The potential clinical applications of proliferative indices are discussed, including their use as prognostic indicators and predictors of response to systemic therapy. IntroductionThe development and continued growth of cancers involves altered rates of cell proliferation. In early breast cancer, measurement of proliferation can be used in conjunction with tumour size, grade, nodal status and steroid receptor status as a prognostic indicator [1,2]. Proliferation rates can provide useful information on prognosis and aggressiveness of individual cancers and can be used to guide treatment protocols in clinical practice. Adjuvant chemotherapy has been shown to improve survival in patients with breast cancer, but has potentially serious side effects. The potential of prognostic factors is to determine which patients are at higher risk of recurrence such that patients who stand to benefit more from adjuvant treatment can be identified. In the future, changes in proliferation rates during or after systemic therapy may be utilized as predictors of response and allow further tailoring of therapy. Information on proliferation rates is also necessary for the development of therapeutic agents, some of which may be targeted directly at specific points in the cell division pathway.Various techniques have been developed to evaluate and quantify proliferation rates in the laboratory. Mitotic count estimates are widely used as a simple measure of cellular proliferation and are often incorporated into tumour grading systems [3]. Other methods have been developed, such as the detection of cells undergoing DNA synthesis using assays for thymidine uptake [4], flow cytometry to estimate the percentage of cells in S phase of the cell cycle or the detection of antigens associated with proliferation. This review will discuss current and developmental methods for assessing proliferation and the potential applications of such knowledge in the treatment of breast cancer. Table 1 summarises these methods and highlights their individual advantages and limitations. Mitotic indexCellular proliferation involves several defined phases. Cells in the resting (G0) phase are stimulated to enter the active cycle at the first gap (G1) phase. During this period of time, the cell prepares for DNA synthesis (the S phase), which is followed by a second phase of relative inactivity (G2) and preparation for the separation of the chromatids in the mitotic (M) phase. Cells can then recycle by entering the G1 phase or return to the resting G0 phase. Proliferation was first measured by counting mitotic bodies on paraffin-embedded tumour specimens stained using haematoxylin-eo...

show abstract

“…Early studies showed that BrdU is as accurate as [3H]-T in providing estimates of S-phase fractions in labeling-index assays and by bivariate flow cytomeuy (3)(4)(5)(6)(7)10,19). Other investigators measured [3H]-T and BrdU incorporation simultaneously and found that the same cells develop positively for both precursor analogues (5,6,(20)(21)(22)(23). To our knowledge, the present work is the first in which DNA content as well as BrdU and [3H]-T incorporation has been measured for the same cells.…”

Section: Discussionmentioning

confidence: 50%

Measurement of DNA content and of tritiated thymidine and bromodeoxyuridine incorporation by the same cells.

Lin¹,

Allison²

1993

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

Flash labelling of S‐phase cells in short‐term organ culture of normal and pathological human endometrium using bromodeoxyuridine and tritiated thymidine

Cited by 40 publications

References 16 publications

Effects of Ovarian Steroids on Uterine Growth, Morphology, and Cell Proliferation in Ovariectomized, Steroid-Treated Ewes1

Effects of Ovarian Steroids on Uterine Growth, Morphology, and Cell Proliferation in Ovariectomized, Steroid-Treated Ewes1

Measuring proliferation in breast cancer: practicalities and applications

Measurement of DNA content and of tritiated thymidine and bromodeoxyuridine incorporation by the same cells.

Contact Info

Product

Resources

About